Nykode Therapeutics aktie (NYKD) | Pressmeddelande

Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at PEGS Europe

GlobeNewswire • 06 Nov 17:00

Nykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based Vaccines

GlobeNewswire • 14 Aug 07:00

Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting

GlobeNewswire • 20 Jun 07:00

Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy

GlobeNewswire • 11 Jun 07:00

Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer

Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.

GlobeNewswire • 14 May 07:15

Nykode Therapeutics - Quarterly report Q1 2024

GlobeNewswire • 14 May 07:00

Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer

Nykode Therapeutics Initiates Phase 2 Trial of VB10.

GlobeNewswire • 19 Apr 07:00

Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer

Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in ...

GlobeNewswire • 21 Mar 07:00

Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases

GlobeNewswire • 19 Mar 07:00

Nykode Therapeutics - Quarterly report Q3 2023

GlobeNewswire • 15 Nov 2023 10:30

Nykode Therapeutics to Present at the mRNA Cancer Vaccines Summit 2023 in Boston

GlobeNewswire • 09 Oct 2023 06:45

Nykode Therapeutics Announces Advances in Clinical Pipeline and Research

GlobeNewswire • 20 Sep 2023 16:06

Nykode Therapeutics Announces FDA Approval of IND for VB-C-04, a Trial of VB10.16 in HPV16-Positive Cervical Cancer

Nykode Therapeutics Announces FDA Approval of IND for VB-C-04, a Trial of VB10.

GlobeNewswire • 05 Sep 2023 07:00

Nykode Therapeutics - Quarterly report Q2 2023

GlobeNewswire • 23 Aug 2023 06:45

Nykode Therapeutics Announces Expansion of Clinical Collaboration with Roche to Evaluate VB10.16 in Combination with anti-PD-L1 in the next trial in Advanced Cervical Cancer

Nykode Therapeutics Announces Expansion of Clinical Collaboration with Roche to Evaluate VB10.

GlobeNewswire • 01 Jun 2023 06:45

Nykode Therapeutics to Present at Jefferies Healthcare Conference

GlobeNewswire • 30 May 2023 18:00

Nykode Therapeutics announces positive final results from its Phase 2 trial of VB10.16 in combination with PD-L1 inhibitor atezolizumab in advanced cervical cancer

Nykode Therapeutics announces positive final results from its Phase 2 trial of VB10.

GlobeNewswire • 18 Apr 2023 17:00

Nykode Therapeutics to announce financial results for the fourth quarter 2022 and host webcast presentation on February 28, 2023

GlobeNewswire • 22 Feb 2023 13:00

Nykode Therapeutics Announces Collaboration with The GOG Foundation, Inc. to Conduct the VB-C-04 Trial in Advanced Cervical Cancer

Nykode Therapeutics Announces Collaboration with The GOG Foundation, Inc.

GlobeNewswire • 10 Feb 2023 06:45

Nykode Therapeutics to Present at SVB Securities Global Biopharma Conference

GlobeNewswire • 07 Feb 2023 13:00

Nykode Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Nykode Therapeutics to Present at the 41st Annual J.

GlobeNewswire • 23 Dec 2022 11:00

Nykode announces expanded clinical development plan for its lead cancer vaccine VB10.16 in HPV16-positive cancers

Nykode announces expanded clinical development plan for its lead cancer vaccine VB10.

GlobeNewswire • 20 Dec 2022 06:45

Nykode Therapeutics and Richter-Helm BioLogics Announce Strategic Manufacturing Partnership

GlobeNewswire • 19 Dec 2022 06:45

Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination With KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive Head and Neck Cancer

Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.

GlobeNewswire • 06 Dec 2022 16:45

Nykode Therapeutics to announce financial results for the third quarter 2022 and host webcast presentation on November 23, 2022

GlobeNewswire • 16 Nov 2022 16:00

Nykode Therapeutics to present at two upcoming investor conferences in November

GlobeNewswire • 07 Nov 2022 08:00

Nykode Therapeutics Announces Presentation of Positive Immunogenicity Results from Phase 1/2a Study of VB10.NEO, an Individualized Therapeutic Cancer Vaccine, at the Neoantigen-Based Therapies Summit

Nykode Therapeutics Announces Presentation of Positive Immunogenicity Results from Phase 1/2a Study of VB10.

GlobeNewswire • 26 Oct 2022 16:30

Nykode Therapeutics Announces Positive Results from the Phase 1/2 Open Label, Dose Escalation Trial of its T Cell Focused SARS-CoV-2 Vaccine Candidate

Nykode Therapeutics Announces Positive Results from the Phase 1/2 Open Label, Dose Escalation Trial of its T Cell Focused SARS-CoV-2 Vaccine...

GlobeNewswire • 27 Sep 2022 06:45

Nykode Therapeutics to present at H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire • 09 Sep 2022 17:00

Nykode Therapeutics to announce financial results for the first half of 2022 and host webcast presentation on August 24, 2022

GlobeNewswire • 22 Aug 2022 06:45

Nykode Therapeutics uplisted to the main list of the Oslo Stock Exchange

GlobeNewswire • 16 Jun 2022 09:00

Nykode Therapeutics to Present at Jefferies Healthcare Conference

GlobeNewswire • 01 Jun 2022 08:00

Nykode Therapeutics announces positive interim results from its Phase 2 trial with VB10.16 in combination with immune checkpoint inhibitor atezolizumab in advanced cervical cancer

Nykode Therapeutics announces positive interim results from its Phase 2 trial with VB10.

GlobeNewswire • 09 May 2022 06:45

Nykode Therapeutics announces presentation of preclinical data from its second generation Vaccibody vaccine technology at 2022 American Association for Cancer Research (AACR) Annual Meeting

Nykode Therapeutics announces presentation of preclinical data from its second generation Vaccibody vaccine technology at 2022 American Asso...

GlobeNewswire • 08 Apr 2022 19:00

Nykode Therapeutics to Present at 2022 American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire • 08 Mar 2022 22:30

Nykode Therapeutics to Present at SVB Leerink 2022 Global Healthcare Conference

GlobeNewswire • 14 Feb 2022 06:45

Nykode Therapeutics announces completion of patient enrollment in its Phase 2 trial of VB10.16 in combination with atezolizumab for the treatment of advanced cervical cancer

Nykode Therapeutics announces completion of patient enrollment in its Phase 2 trial of VB10.

GlobeNewswire • 11 Feb 2022 06:45

Nykode Therapeutics announces first subject dosed with its T cell focused next-generation SARS-CoV-2 vaccine candidate

GlobeNewswire • 28 Dec 2021 06:45

Börskollen

För dig med koll på börsen

Pressmeddelanden från Nykode Therapeutics

Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at PEGS Europe

Nykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based Vaccines

Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting

Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy

Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer

Nykode Therapeutics - Quarterly report Q1 2024

Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer

Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer

Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases

Nykode Therapeutics - Quarterly report Q3 2023

Nykode Therapeutics to Present at the mRNA Cancer Vaccines Summit 2023 in Boston

Nykode Therapeutics Announces Advances in Clinical Pipeline and Research

Nykode Therapeutics Announces FDA Approval of IND for VB-C-04, a Trial of VB10.16 in HPV16-Positive Cervical Cancer

Nykode Therapeutics - Quarterly report Q2 2023

Nykode Therapeutics Announces Expansion of Clinical Collaboration with Roche to Evaluate VB10.16 in Combination with anti-PD-L1 in the next trial in Advanced Cervical Cancer

Nykode Therapeutics to Present at Jefferies Healthcare Conference

Nykode Therapeutics announces positive final results from its Phase 2 trial of VB10.16 in combination with PD-L1 inhibitor atezolizumab in advanced cervical cancer

Nykode Therapeutics to announce financial results for the fourth quarter 2022 and host webcast presentation on February 28, 2023

Nykode Therapeutics Announces Collaboration with The GOG Foundation, Inc. to Conduct the VB-C-04 Trial in Advanced Cervical Cancer

Nykode Therapeutics to Present at SVB Securities Global Biopharma Conference

Nykode Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Nykode announces expanded clinical development plan for its lead cancer vaccine VB10.16 in HPV16-positive cancers

Nykode Therapeutics and Richter-Helm BioLogics Announce Strategic Manufacturing Partnership

Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination With KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive Head and Neck Cancer

Nykode Therapeutics to announce financial results for the third quarter 2022 and host webcast presentation on November 23, 2022

Nykode Therapeutics to present at two upcoming investor conferences in November

Nykode Therapeutics Announces Presentation of Positive Immunogenicity Results from Phase 1/2a Study of VB10.NEO, an Individualized Therapeutic Cancer Vaccine, at the Neoantigen-Based Therapies Summit

Nykode Therapeutics Announces Positive Results from the Phase 1/2 Open Label, Dose Escalation Trial of its T Cell Focused SARS-CoV-2 Vaccine Candidate

Nykode Therapeutics to present at H.C. Wainwright 24th Annual Global Investment Conference

Nykode Therapeutics to announce financial results for the first half of 2022 and host webcast presentation on August 24, 2022

Nykode Therapeutics uplisted to the main list of the Oslo Stock Exchange

Nykode Therapeutics to Present at Jefferies Healthcare Conference

Nykode Therapeutics announces positive interim results from its Phase 2 trial with VB10.16 in combination with immune checkpoint inhibitor atezolizumab in advanced cervical cancer

Nykode Therapeutics announces presentation of preclinical data from its second generation Vaccibody vaccine technology at 2022 American Association for Cancer Research (AACR) Annual Meeting

Nykode Therapeutics to Present at 2022 American Association for Cancer Research (AACR) Annual Meeting

Nykode Therapeutics to Present at SVB Leerink 2022 Global Healthcare Conference

Nykode Therapeutics announces completion of patient enrollment in its Phase 2 trial of VB10.16 in combination with atezolizumab for the treatment of advanced cervical cancer

Nykode Therapeutics announces first subject dosed with its T cell focused next-generation SARS-CoV-2 vaccine candidate